4.6 Article

Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease

期刊

MOVEMENT DISORDERS
卷 33, 期 5, 页码 839-843

出版社

WILEY
DOI: 10.1002/mds.27335

关键词

cognitive data; neuropsychology; Parkinson's disease

资金

  1. Michael J. Fox Foundation for Parkinson's Research
  2. Abbvie
  3. Avid Radiopharmaceuticals
  4. Biogen
  5. Britsol-Myers Squibb
  6. Covance
  7. GE Healthcare
  8. Genetech
  9. GlaxoSmithKline
  10. Lilly
  11. Lundbeck
  12. Merck
  13. Meso Scale Discovery
  14. Pfizer
  15. Piramal
  16. Roche
  17. Servier
  18. UCB

向作者/读者索取更多资源

Objective: The objective of this study was to examine the impact of different methods of standardizing cognitive data in the Parkinson's Progression Marker Initiative. Methods: Cognitive data from 423 participants with Parkinson's disease were included (age=61.7 [9.7], education=15.6 [3.0]). Internal norms were calculated using the group mean and standard deviation of the healthy control group. Published norms were compared to the overall group mean of and to age-stratified norms from healthy controls for each neuropsychological test over 4 visits. Rates of mild cognitive impairment were calculated using established criteria. Results: The use of internal norms resulted in lower standardized scores than published norms on all tests with the exception of memory and processing speed (P.001). Individuals were 1.5 to 2.1 times more likely to be diagnosed with mild cognitive impairment using internal norms than published norms. Conclusions: Standardization approaches with cognitive data are not interchangeable. Selection of a normative comparison group impacts research and clinical interpretations of cognitive data. (c) 2018 International Parkinson and Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据